BOSTON & SAN FRANCISCO--(BUSINESS WIRE)--Pear Therapeutics, Inc., the leader in prescription digital therapeutics (PDTs), today announced that Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual panel discussion entitled “Emerging World of Digital Therapeutics” at the SVB Leerink CybeRx Series: Digital Health – Innovators & Disruptors on Thursday, May 21 at 12:35 p.m. Eastern Time.
About Pear Therapeutics
Pear Therapeutics is the leader in prescription digital therapeutics, or PDTs. Pear aims to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas. Pear’s lead product, reSET®, for the treatment of Substance Use Disorder, was the first PDT to receive marketing authorization from FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of Opioid Use Disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst™ for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com.